147 related articles for article (PubMed ID: 19417030)
1. Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology.
Li R; Dai H; Wheeler TM; Sayeeduddin M; Scardino PT; Frolov A; Ayala GE
Clin Cancer Res; 2009 May; 15(10):3568-73. PubMed ID: 19417030
[TBL] [Abstract][Full Text] [Related]
2. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence.
Ayala G; Thompson T; Yang G; Frolov A; Li R; Scardino P; Ohori M; Wheeler T; Harper W
Clin Cancer Res; 2004 Oct; 10(19):6572-8. PubMed ID: 15475446
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
5. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men.
Shimizu Y; Segawa T; Inoue T; Shiraishi T; Yoshida T; Toda Y; Yamada T; Kinukawa N; Terada N; Kobayashi T; Kinoshita H; Kamoto T; Nakamura E; Ogawa O
BJU Int; 2007 Sep; 100(3):685-90. PubMed ID: 17542985
[TBL] [Abstract][Full Text] [Related]
6. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.
Aaltomaa S; Kärjä V; Lipponen P; Isotalo T; Kankkunen JP; Talja M; Mokka R
Anticancer Res; 2006; 26(6C):4873-8. PubMed ID: 17214354
[TBL] [Abstract][Full Text] [Related]
7. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression.
Yang G; Timme TL; Frolov A; Wheeler TM; Thompson TC
Cancer; 2005 Mar; 103(6):1186-94. PubMed ID: 15712208
[TBL] [Abstract][Full Text] [Related]
8. Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system.
Descazeaud A; de la Taille A; Allory Y; Faucon H; Salomon L; Bismar T; Kim R; Hofer MD; Chopin D; Abbou CC; Rubin MA
Prostate; 2006 Jul; 66(10):1037-43. PubMed ID: 16598739
[TBL] [Abstract][Full Text] [Related]
9. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.
Osman I; Dai J; Mikhail M; Navarro D; Taneja SS; Lee P; Christos P; Shen R; Nanus DM
Cancer; 2006 Dec; 107(11):2628-36. PubMed ID: 17083125
[TBL] [Abstract][Full Text] [Related]
10. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy.
Donovan MJ; Hamann S; Clayton M; Khan FM; Sapir M; Bayer-Zubek V; Fernandez G; Mesa-Tejada R; Teverovskiy M; Reuter VE; Scardino PT; Cordon-Cardo C
J Clin Oncol; 2008 Aug; 26(24):3923-9. PubMed ID: 18711180
[TBL] [Abstract][Full Text] [Related]
11. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model.
Diallo JS; Aldejmah A; Mouhim AF; Péant B; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2007 Dec; 13(23):7044-52. PubMed ID: 18056181
[TBL] [Abstract][Full Text] [Related]
12. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
[TBL] [Abstract][Full Text] [Related]
14. Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.
Rouprêt M; Hupertan V; Comperat E; Drouin SJ; Phé V; Xylinas E; Demanse D; Sibony M; Richard F; Cussenot O
BJU Int; 2009 Sep; 104(6):813-7; discussion 817-8. PubMed ID: 19254280
[TBL] [Abstract][Full Text] [Related]
15. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
[TBL] [Abstract][Full Text] [Related]
16. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.
Fleischmann A; Schlomm T; Köllermann J; Sekulic N; Huland H; Mirlacher M; Sauter G; Simon R; Erbersdobler A
Prostate; 2009 Jun; 69(9):976-81. PubMed ID: 19274666
[TBL] [Abstract][Full Text] [Related]
17. Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy.
van Roermund JG; Kok DE; Wildhagen MF; Kiemeney LA; Struik F; Sloot S; van Oort IM; Hulsbergen-van de Kaa CA; van Leenders GJ; Bangma CH; Witjes JA
BJU Int; 2009 Aug; 104(3):321-5. PubMed ID: 19220264
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer.
Parker AS; Heckman MG; Wu KJ; Crook JE; Hilton TW; Pisansky TM; Bernard JR; Schild SE; Khor LY; Hammond EH; Pollack A; Buskirk SJ
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1364-70. PubMed ID: 19464826
[TBL] [Abstract][Full Text] [Related]
19. Quantitative fluorescence imaging analysis for cancer biomarker discovery: application to beta-catenin in archived prostate specimens.
Huang D; Casale GP; Tian J; Wehbi NK; Abrahams NA; Kaleem Z; Smith LM; Johansson SL; Elkahwaji JE; Hemstreet GP
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1371-81. PubMed ID: 17623804
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy.
Fuchsjäger MH; Shukla-Dave A; Hricak H; Wang L; Touijer K; Donohue JF; Eastham JA; Kattan MW
BJU Int; 2009 Aug; 104(3):315-20. PubMed ID: 19220263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
